Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CNDO-109||CNDO-109-AANK cells||CNDO-109 is a cell lysate obtained from the CTV-1 leukemia cell line, which potentially stimulates natural killer cell activity, leading to tumor cell lysis (PMID: 29597002).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute leukemia||not applicable||CNDO-109||Phase I||Actionable||In a Phase I trial, acute leukemia patients treated with CNDO-109 demonstrated a relapse-free survival (RFS) rate of 33% at 12 months, with three patients demonstrating a long-term RFS of at least 32.6 months in a follow-up (PMID: 29597002; NCT01520558).||29597002|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|